Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168787 · ClinicalTrials.gov registry record
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 6,558
- Enrollment target
NCT05168787: Completed study, sponsored by Methodist Health System.
NCT05168787 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 6,558 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05168787 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 6,558 participants
- Enrollment target
Study Summary
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, there is the potential that the mechanism of action of sacubitril/valsartan may be less effective in AAs.
Primary Outcome
Composite CV mortality or HF hospitalization
Interventions
- DRUG sacubitril/valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,558 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2025-07-08 |
What the finished NCT05168787 record still lists
NCT05168787 is an observational study that tracks outcomes without assigning an intervention. Its 6,558 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which sacubitril/valsartan is the first listed.
NCT05168787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05168787 about?
NCT05168787 is a clinical study titled "Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction". There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general. However, the mechanism of action of sacubitril specifically targets the activity of BNP. Therefore, the...
What is the current status of trial NCT05168787?
This trial is currently completed. The enrollment target is 6,558 participants. The study started on 2020-08-13. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05168787?
The interventions under investigation include: sacubitril/valsartan (DRUG).
Who is sponsoring clinical trial NCT05168787?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI